An observational study in Non-Occlusive Mesenteric Ischemia, sponsored by University of Tartu. Active, not recruiting at 1 site in Estonia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-14.
Sponsored by University of Tartu · Observational
This prospective multicenter observational study, conducted between June , 2022, and April, 2023, is a preplanned analysis of the AMESI study titled 'Demographics, diagnosis, management, and outcomes of non-occlusive mesenteric ischemia,' aiming primarily to describe the demographic profile, clinical presentation, and laboratory findings of patients with non-occlusive mesenteric ischemia (NOMI), and secondarily to identify independent risk factors as well as diagnostic approaches, management strategies, and outcomes-including in-hospital, 90-day, and one-year results.
40 studies on the registry are indexed under Mesenteric Ischemia; 14 are open to participants now.
This study's enrollment of 566 is above the median of 154 across 26 observational studies indexed under Mesenteric Ischemia.
Browse Mesenteric Ischemia studies →University of Tartu is the lead sponsor of 46 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Study groups
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All at least 18-year-old patients with acute mesenteric ischemia or patients suspected of acute mesenteric ischemia that was not confirmed
Exclusion Criteria:
Patients with non-occlusive mesenteric ischemia, n=55
Other: No intervention
Patients with arterial occlusive mesenteric ischemia, n=231
Other: No intervention
Patients with arterial occlusive mesenteric ischemia, n=73
Other: No intervention
Patients with unclear mechanism of acute mesenteric ischemia, n=48
Other: No intervention
Patients with suspected but not confirmed acute mesenteric ischemia, n=159
Other: No intervention
No intervention, this is an observational study on patients with suspected acute mesenteric ischemia
Demographic profile
One of the primary objectives is to describe the baseline demographic profile of patients with non-occlusive mesenteric ischemia. The demographic data will include the following information: 1. Gender (Male or Female) 2. Age (in years) 3. BMI (calculated from body weight in kilograms and height in centimeters)
Time frame: Baseline
SOFA score
Sequential Organ Failure Assessment (SOFA) score. Range: 0-24. Higher scores indicate more severe organ dysfunction.
Time frame: Baseline
Serum Lactate Levels in Patients with Non-Occlusive Mesenteric Ischemia
Serum lactate level measured in mmol/L. Higher values indicate worse tissue perfusion.
Time frame: Baseline
Baseline APACHE II Score
Acute Physiology and Chronic Health Evaluation II (APACHE II) score. Range: 0-71. Higher scores indicate more severe disease and higher predicted mortality.
Time frame: Baseline
Arterial Blood pH in Patients with Non-Occlusive Mesenteric Ischemia
Arterial pH level. Normal range is 7.35-7.45. Lower values indicate acidosis.
Time frame: Baseline
Rate of Patients Diagnosed with Non-Occlusive Mesenteric Ischemia by CT, Endoscopy, or Angiography
Percentage of participants diagnosed with non-occlusive mesenteric ischemia (NOMI) using computed tomography (CT), endoscopy, or angiography.
Time frame: Baseline
Management
Rate of surgical, conservative, endovascular or palliative management
Time frame: Baseline
30-day survival
30-day Survival of patients with non-occlusive mesenteric ischemia
Time frame: 30 days after admission
1-year survival
1-year survival of patients with non-occlusive mesenteric ischemia
Time frame: 1 year
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Jun 2022 to primary completion in Apr 2023, 9 months.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Tartu